Weiqi Jiao

Qingdao University, Affiliated Hospital of Qingdao University

Papers

2

Total Citations

13

H-Index

2

About

No biography available yet.

Research Focus

Neoadjuvant therapy1 · 10 citations
Oncology1 · 10 citations
Internal medicine1 · 10 citations
Medicine1 · 10 citations
Adenocarcinoma1 · 10 citations
Clinical trial1 · 10 citations
Breast cancer1 · 10 citations
Adverse effect1 · 10 citations
Cancer1 · 10 citations
Lung cancer1 · 10 citations
Clinical endpoint1 · 10 citations
Osimertinib1 · 10 citations

Key Achievements

2
H-Index
2
Papers
13
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
10 citations · 2022
📈 Most Prolific Year: 2022 (2 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Qingdao University, Affiliated Hospital of Qingdao University

Top Papers

  1. 1
    81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
    10 citations · 2022
  2. 2
    [Problems to be solved in the development from the perspective of future application scenarios of telesurgery].
    3 citations · 2022

Key Collaborators

CJChuhl Joo Lyu1 shared papersRWR. Wang1 shared papersNWNan Wu1 shared papersHNHaitao Niu1 shared papersWFWentao Fang1 shared papersSXS. Xu1 shared papersHMHaitao Ma1 shared papersYYYongbo Yang1 shared papersJMJ M Li1 shared papersJWJ. Wang1 shared papersXZXiaoqun Zhang1 shared papers
Not generated yet